Clinical Trials Logo

Clinical Trial Summary

Inflammatory paranasal diseases are among the most common diseases in ENT In Russia, puncture method has been conventional approach to treatment of maxillary sinusitis. However, this procedure is associated with a number of drawbacks A promising trend for the treatment of purulent sinusitis is a reasonable antibacterial therapy Fluoroquinolones, particularly levofloxacin, are highly active against pneumonocci and are more active vs. the drug products of the second generation against intracellular agents (Chlamydia spp., Mycoplasma spp., M. tuberculosis, rapidly growing atypical mycobacteria (M. avium, etc.).

Due to high activity against the agents causing bacterial upper and lower respiratory tract infections they are sometimes called "respiratory" fluoroquinolones


Clinical Trial Description

Inflammatory diseases of paranasal sinuses occupy one of the leading positions in the overall structure of ENT-diseases.

Puncture method has been a conventional approach to the treatment of suppurative maxillary sinusitis in Russia until present. However, this relatively simple and conventional treatment method has a number of disadvantages. Fear of an unpleasant procedure is justified. Generally, single puncture does not ensure healing, and the doctor has to install drainage or of perform repeated manipulations significantly reducing quality of life during the disease period. There is also a certain risk of puncture needle penetration into adjacent areas. Sometimes direct contraindications to punctures exist (intolerance of topical anesthetics, blood clotting disorders, etc.).

The puncture itself, as an independent method, is a relieving procedure rather than a pathognomonic treatment method, especially regarding severe combined forms of sinusitis with risk of intracranial complications. Due to lacking standardized antibacterial drugs to be injected into the sinus, multiple punctures are erroneously considered to be able of eliminating the bacterial agent successfully.

One of the promising trends regarding the treatment of suppurative maxillary sinusitis is an adequate antibacterial therapy. Fluoroquinolones of last generations, levofloxacin in particular, which are highly active against pneumococci, are more effective vs. generation II drugs against intracellular agents (Chlamydia spp., Mycoplasma spp., M.tuberculosis, rapidly growing atypical mycobacteria (M.avium, etc.). At that activity towards other gram-negative bacteria is not reduced. An important property of these drugs consists in activity regarding a number of bacteria resistant to generation II fluoroquinolones. Due to high activity against the agents of upper and lower respiratory bacterial infections they are sometimes called "respiratory" fluoroquinolones.

According to a publication, Levofloxacin 500 mg q.d. for 5 days eliminated radiological signs of the disease by the end of the course in 65% subjects, while 35% showed positive changes only (М.А. Panyakina, 2012). Based on these findings, otolaryngologists have to obtain higher therapeutic efficacy levels with the same 5-day course, since this treatment term demonstrates violated compliance most frequently. One of the options is an elevation of daily dose. In particular, Rameez Shah (2013) published data concerning high efficacy of levofloxacin at a daily dose of 750 mg for 5 days.

Necessity to search ways to shorten the current course of antibiotic therapy is being under discussion at all levels. Particularly, 24th European Congress of Clinical Microbiology and Infectious Diseases performed on May 10-13, 2014 in Barcelona (ECCMID 2014) repeatedly raised question concerning revision of the current treatment standards and clinical recommendations concerning duration of antibiotic therapy and dosing regimens.

Based on the above-mentioned findings, it would be interesting to evaluate efficacy of various antibiotic schemes (respiratory fluoroquinolones or protected aminopenicillin) in hospital conditions. ;


Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02712502
Study type Observational
Source Dr. Reddy's Laboratories Limited
Contact
Status Completed
Phase N/A
Start date September 2014
Completion date December 2014

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02636790 - Early Versus Late Surgical Wait Times Early Phase 1
Completed NCT00986830 - Healthcare Utilization and Outcomes of FinESS Treatment in the Office N/A
Completed NCT00534079 - Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis Phase 3
Completed NCT05442606 - Physiotherapy Protocol in Treating Chronic Rhinosinusitis N/A
Completed NCT01955980 - Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis Phase 1/Phase 2
Completed NCT04123405 - Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis Phase 3
Completed NCT00797004 - Olfactory Dysfunction of Rhinosinusitis N/A
Recruiting NCT05494346 - Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction N/A
Not yet recruiting NCT05836935 - Role of Imaging in Complications of Sinusitis N/A
Withdrawn NCT02097576 - Manuka Honey Nasal Rinse Study N/A
Completed NCT01132781 - Theophylline in Rhinitis Phase 2
Recruiting NCT00948519 - Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents N/A
Completed NCT00554190 - Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel Phase 4
Recruiting NCT03729258 - Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis. Phase 3
Withdrawn NCT03729310 - Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis Early Phase 1
Recruiting NCT01296919 - The Clinical Significance of the Uncinate Process Histopathology in Chronic Rhinosinusitis N/A
Completed NCT01086839 - Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis N/A
Completed NCT00849953 - FinESS Registry Study N/A
Withdrawn NCT00669799 - Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study N/A
Completed NCT03229551 - Xylitol for Chronic Sinusitis Phase 2/Phase 3